Clinical trial
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell…
NCT00111020 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00111020 |
|---|---|
| Title | Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma |
| Official title | Open Label, Non-Comparative Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006) |
| Enrollment | 2,567 |
| Start date | Jun 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Oct 1, 2008 |
| First posted | May 17, 2005 |
| Last update posted | Aug 6, 2014 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: